439 related articles for article (PubMed ID: 30791936)
21. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
[TBL] [Abstract][Full Text] [Related]
22. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature.
Giordanetto F; Karis D
Expert Opin Ther Pat; 2012 Dec; 22(12):1467-77. PubMed ID: 23136886
[TBL] [Abstract][Full Text] [Related]
23. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
24. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
25. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
26. TQFL12, a novel synthetic derivative of TQ, inhibits triple-negative breast cancer metastasis and invasion through activating AMPK/ACC pathway.
Wei C; Zou H; Xiao T; Liu X; Wang Q; Cheng J; Fu S; Peng J; Xie X; Fu J
J Cell Mol Med; 2021 Nov; 25(21):10101-10110. PubMed ID: 34609056
[TBL] [Abstract][Full Text] [Related]
27. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
Son D; Kim Y; Lim S; Kang HG; Kim DH; Park JW; Cheong W; Kong HK; Han W; Park WY; Chun KH; Park JH
Cancer Lett; 2019 Jul; 454():224-233. PubMed ID: 31004703
[TBL] [Abstract][Full Text] [Related]
28. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
29. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
30. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
31. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
32. Promise and challenges for direct small molecule AMPK activators.
Olivier S; Foretz M; Viollet B
Biochem Pharmacol; 2018 Jul; 153():147-158. PubMed ID: 29408352
[TBL] [Abstract][Full Text] [Related]
33. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor β-activated kinase 1 inhibitor suppresses the proliferation in triple-negative breast cancer through TGF-β/TGFR pathway.
Zhang L; Fu Z; Li X; Tang H; Luo J; Zhang D; Zhuang Y; Han Z; Yin M
Chem Biol Drug Des; 2017 Sep; 90(3):450-455. PubMed ID: 28224764
[TBL] [Abstract][Full Text] [Related]
35. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
36. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
37. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
[TBL] [Abstract][Full Text] [Related]
38. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
39. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.
Popovics P; Frigo DE; Schally AV; Rick FG
Expert Opin Ther Targets; 2015 May; 19(5):617-32. PubMed ID: 25600663
[TBL] [Abstract][Full Text] [Related]
40. Targeting PI3K and AMPKα Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer.
Johnson J; Chow Z; Napier D; Lee E; Weiss HL; Evers BM; Rychahou P
Cells; 2020 May; 9(5):. PubMed ID: 32438621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
